Yau Anne, Lee Jinhyung, Chen Yupeng
Department of Biomedical Engineering, University of Connecticut, Storrs, CT 06269, USA.
Pharmaceutics. 2021 Jan 25;13(2):155. doi: 10.3390/pharmaceutics13020155.
Nanotechnology platforms, such as nanoparticles, liposomes, dendrimers, and micelles have been studied extensively for various drug deliveries, to treat or prevent diseases by modulating physiological or pathological processes. The delivery drug molecules range from traditional small molecules to recently developed biologics, such as proteins, peptides, and nucleic acids. Among them, proteins have shown a series of advantages and potential in various therapeutic applications, such as introducing therapeutic proteins due to genetic defects, or used as nanocarriers for anticancer agents to decelerate tumor growth or control metastasis. This review discusses the existing nanoparticle delivery systems, introducing design strategies, advantages of using each system, and possible limitations. Moreover, we will examine the intracellular delivery of different protein therapeutics, such as antibodies, antigens, and gene editing proteins into the host cells to achieve anticancer effects and cancer vaccines. Finally, we explore the current applications of protein delivery in anticancer treatments.
纳米技术平台,如纳米颗粒、脂质体、树枝状大分子和胶束,已被广泛研究用于各种药物递送,通过调节生理或病理过程来治疗或预防疾病。递送的药物分子范围从传统小分子到最近开发的生物制品,如蛋白质、肽和核酸。其中,蛋白质在各种治疗应用中显示出一系列优势和潜力,例如由于基因缺陷引入治疗性蛋白质,或用作抗癌剂的纳米载体以减缓肿瘤生长或控制转移。本综述讨论了现有的纳米颗粒递送系统,介绍了设计策略、使用每种系统的优势以及可能的局限性。此外,我们将研究不同蛋白质治疗剂,如抗体、抗原和基因编辑蛋白在宿主细胞中的细胞内递送,以实现抗癌效果和癌症疫苗。最后,我们探讨蛋白质递送在抗癌治疗中的当前应用。
Pharmaceutics. 2021-1-25
Eur J Pharm Biopharm. 2015-6
Nanomedicine (Lond). 2015-7
Nanomedicine. 2011-6-7
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017-1
Chin J Cancer. 2010-9
Cell Commun Signal. 2024-10-16
Biomolecules. 2024-8-27
Front Biomater Sci. 2023
Front Space Technol. 2023
Nucl Acid Insights. 2024-3
Micromachines (Basel). 2024-4-15
Front Chem. 2024-1-18
Juniper Online J Mater Sci. 2019-9
Nat Rev Drug Discov. 2021-2
Mol Cancer. 2020-11-12
J Control Release. 2021-1-10
Bioengineering (Basel). 2020-9-14
Antibodies (Basel). 2020-7-20
CA Cancer J Clin. 2020-7-8
Bioact Mater. 2020-6-30